Cited by 2,409Glioma Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Response criteria for phase II studies of supratentorial malignant glioma.

Macdonald, D R, Cascino, T L, Schold, S C, Cairncross, J G·1990·Journal of Clinical Oncology

DOI 10.1200/jco.1990.8.7.1277

Open this paper in CoChat — free account

Abstract

We suggest "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications. Four response categories are proposed: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Response in this scheme is based on major changes in tumor size on the enhanced computed tomographic (CT) or magnetic resonance imaging (MRI) scan. Scan changes are interpreted in light of steroid use and neurologic findings. We advocate careful patient selection, emphasize pitfalls in the assessment of response, and suggest guidelines to minimize misinterpretations of response.

Integrity signals

Registry

Crossref · 10.1200/jco.1990.8.7.1277

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Successful chemotherapy for recurrent malignant oligodendroglioma
Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 345
Self-citation
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors
Levin, V. A., Crafts, D. C., Norman, D. M., Hoffer, P. B., Spire, J., & Wilson, C. B. (1977) · Journal of neurosurgery · doi:10.3171/jns.1977.47.3.0329 · Cited by 199
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone, A., Longo, D. L., Vt, D., Ihde, D. C., Duffey, P. L., Jaffe, E. S., Solomon, D., HUBBARD, S. M., & Young, R. C. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1832 · Cited by 178
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.
Warr, D. G., McKinney, S., & Tannock, I. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.9.1040 · Cited by 151
Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas
Chamberlain, M. C., Murovic, J. A., & Levin, V. A. (1988) · Neurology · doi:10.1212/wnl.38.9.1371 · Cited by 149
Steroid‐induced CT changes in patients with recurrent malignant glioma
Cairncross, J. G., Macdonald, D. R., Pexman, J. H. W., & Ives, F. J. (1988) · Neurology · doi:10.1212/wnl.38.5.724 · Cited by 100
Self-citation
Computerized tomography in the prognosis of malignant cerebral gliomas
Murovic, J. A., Turowski, K., Wilson, C. B., Hoshino, T., & Levin, V. A. (1986) · Journal of neurosurgery · doi:10.3171/jns.1986.65.6.0799 · Cited by 42
Criteria and definitions for response and relapse in children with brain tumors
Zeltzer, P. M., Friedman, H. S., Norris, D. G., & Ragab, A. H. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7+ · Cited by 35
Post-Surgical Contrast Enhancement Mimicking Residual Brain Tumour
Cairncross, J. G., Pexman, J. H. W., & Rathbone, M. P. (1985) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046643 · Cited by 33
Self-citation
The accuracy of volumetric measurement of high-grade gliomas
Chisholm, R. A., Stenning, S. P., & Hawkins, T. D. (1989) · Clinical Radiology · doi:10.1016/s0009-9260(89)80007-8 · Cited by 32

Flagged first, then by citations

Show all 11 references

Sorted by citations

Items 401–500 of 1,001

New Directions in Anti-Angiogenic Therapy for Glioblastoma
Wang, N., Jain, R. K., & Batchelor, T. T. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0510-y · Cited by 123
Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas
IWAMOTO, F. M., Kreisl, T. N., Kim, L., Duic, J. P., Butman, J. A., Albert, P. S., & Fine, H. A. (2010) · Cancer · doi:10.1002/cncr.24957 · Cited by 121
The role of chemotherapy in brain metastases
van den Bent, M. J. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00577-x · Cited by 121
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
Pope, W. B., Xia, Q., Paton, V. E., Das, A., Hambleton, J., Kim, H. J., Huo, J., Brown, M. S., Goldin, J. G., & Cloughesy, T. F. (2011) · Neurology · doi:10.1212/wnl.0b013e31820a0a8a · Cited by 120
Angiogenesis as a Therapeutic Target in Malignant Gliomas
Chi, A. S., Sorensen, A. G., Jain, R. K., & Batchelor, T. T. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0272 · Cited by 121
Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma
Schmainda, K. M., Prah, M. A., Connelly, J., Rand, S. D., Hoffman, R. G., Mueller, W. M., & Malkin, M. G. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not216 · Cited by 120
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
Kesari, S., Schiff, D., Doherty, L. M., Gigas, D. C., Batchelor, T. T., Muzikansky, A., O’Neill, A., Drappatz, J., Chen‐Plotkin, A. S., Ramakrishna, N. R., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-006 · Cited by 120
Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial
Reni, M., Mason, W. P., Zaja, F. F., Perry, J., Franceschi, E., Bernardi, D., Dell’Oro, S., Stelitano, C. C., Candela, M., Abbadessa, A., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.03.008 · Cited by 120
Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma
Galldiks, N., Stoffels, G., Ruge, M. I., Rapp, M., Sabel, M., Reifenberger, G., Erdem, Z., Shah, N. J., Fink, G. R., Coenen, H. H., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.123836 · Cited by 119
Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations
Brastianos, P. K., Twohy, E. L., Gerstner, E. R., Kaufmann, T. J., Iafrate, A. J., Lennerz, J. K., Jeyapalan, S. A., Piccioni, D. E., Monga, V., Fadul, C. E., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02371 · Cited by 119
Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy
DeLay, M., Jahangiri, A., Carbonell, W. S., Hu, Y., Tsao, S. W., Tom, M. W., Paquette, J., Tokuyasu, T. A., & Aghi, M. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2390 · Cited by 118
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma
Norden, A. D., Ligon, K. L., Hammond, S. N., Muzikansky, A., Reardon, D. A., Kaley, T. J., Batchelor, T. T., Plotkin, S. R., Raizer, J. J., Wong, E. T., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001153 · Cited by 118
Outcome in adult low-grade glioma
Schiff, D., Brown, P. D., & Giannini, C. (2007) · Neurology · doi:10.1212/01.wnl.0000277271.47601.a1 · Cited by 118
Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study
Vredenburgh, J. J., Cloughesy, T. F., Samant, M. K., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0105 · Cited by 117
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
Clarke, J. L., Ennis, M. M., Yung, W. K. A., Chang, S., Wen, P. Y., Cloughesy, T. F., DeAngelis, L. M., Robins, H. I., Lieberman, F. S., Fine, H. A., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor110 · Cited by 117
Antiangiogenic therapy for high-grade glioma
Khasraw, M., Ameratunga, M., Grant, R., Wheeler, H., & Pavlakis, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008218.pub3 · Cited by 119
Circulating glioma biomarkers
Kros, J. M., Mustafa, D. A. M., Dekker, L. J. M., Smitt, P. A. E. S., Luider, T. M., & Zheng, P. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou207 · Cited by 119
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
Lee, E. Q., Kuhn, J. G., Lamborn, K. R., Abrey, L. E., DeAngelis, L. M., Lieberman, F. S., Robins, H. I., Chang, S., Yung, W. K. A., Drappatz, J., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos264 · Cited by 119
Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response
Tamura, R., Tanaka, T., Miyake, K., Yoshida, K., & Sasaki, H. (2017) · Brain Tumor Pathology · doi:10.1007/s10014-017-0284-x · Cited by 116
Interferon‐α for recurrent World Health Organization grade 1 intracranial meningiomas
Chamberlain, M. C., & Glantz, M. (2008) · Cancer · doi:10.1002/cncr.23803 · Cited by 116
A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas
Raizer, J. J., Grimm, S. A., RADEMAKER, A. W., Chandler, J. P., Muro, K., Helenowski, I., Rice, L. C., McCarthy, K., Johnston, S. K., Mrugała, M. M., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1358-9 · Cited by 115
Clinical Evaluation of a Fully-automatic Segmentation Method for Longitudinal Brain Tumor Volumetry
Meier, R., Knecht, U., Loosli, T., Bauer, S., Slotboom, J., Wiest, R., & Reyes, M. (2016) · Scientific Reports · doi:10.1038/srep23376 · Cited by 115
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide
Wahl, M. T., Phillips, J. J., Molinaro, A. M., Lin, Y., Perry, A., Haas-Kogan, D. A., Costello, J., Dayal, M., Butowski, N. A., Clarke, J. L., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now176 · Cited by 116
PCV chemotherapy for recurrent glioblastoma multiforme
Kappelle, A. C., Postma, T. J., TAPHOORN, M. J. B., Groeneveld, G. J., van den Bent, M. J., van Groeningen, C. J., Zonnenberg, B. A., Sneeuw, K. C. A., & Heimans, J. J. (2001) · Neurology · doi:10.1212/wnl.56.1.118 · Cited by 115
Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors
Bessell, E. M., Graus, F., López‐Guillermo, A., Lewis, S., Villà, S., Verger, E., & Petit, J. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.11.001 · Cited by 115
MRI in treatment of adult gliomas
Henson, J. W., Gaviani, P., & González, R. G. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)01767-5 · Cited by 115
Diffusion imaging for evaluation of tumor therapies in preclinical animal models
Moffat, B. A., Hall, D. E., Stojanovska, J., McConville, P., Moody, J. B., Chenevert, T. L., Rehemtulla, A., & Ross, B. D. (2004) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-004-0079-z · Cited by 115
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
Kouwenhoven, M. C. M., Kros, J. M., French, P. J., Stege, E. M. B., Graveland, W. J., TAPHOORN, M. J. B., Brandes, A. A., & van den Bent, M. J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.021 · Cited by 115
Molecular genetic alterations in glioblastomas with oligodendroglial component
Kraus, J. A., Lamszus, K., Glesmann, N., Beck, M., Wolter, M., Sabel, M., Krex, D., Klockgether, T., Reifenberger, G., & Schlegel, U. S. (2001) · Acta Neuropathologica · doi:10.1007/s004010000258 · Cited by 115
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
Lee, E. Q., Kaley, T. J., Duda, D. G., Schiff, D., Lassman, A. B., Wong, E. T., Mikkelsen, T., Purow, B. W., Muzikansky, A., Ancukiewicz, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3220 · Cited by 118
Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging
Park, I., Bok, R., Ozawa, T., Phillips, J. J., James, C. D., Vigneron, D. B., Ronen, S. M., & Nelson, S. J. (2011) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22563 · Cited by 114
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans
Mitchell, D. A., Cui, X., Schmittling, R. J., Sanchez-Perez, L. A., Snyder, D. J., Congdon, K. L., Archer, G. E., Desjardins, A., Friedman, A. H., Friedman, H. S., et al. (2011) · Blood · doi:10.1182/blood-2011-02-334565 · Cited by 114
Reirradiation of primary brain tumours: survival, clinical response and prognostic factors
Veninga, T., Langendijk, J. A., Slotman, B. J., Rutten, E. H. J. M., van der Kogel, A. J., Prick, M. J. J., Keyser, A., & van der Maazen, R. W. M. (2001) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(01)00299-7 · Cited by 114
First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia
Brandes, A. A., Basso, U., Reni, M., Vastola, F., Tosoni, A., Cavallo, G., Scopece, L., Ferreri, A. J. M., Panucci, M. G., Monfardini, S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.019 · Cited by 114
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
de Groot, J., Gilbert, M. R., Aldape, K., Hess, K. R., Hanna, T., Ictech, S. E., Groves, M. D., Conrad, C., Colman, H., Puduvalli, V. K., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9637-y · Cited by 116
Gene Expression Profiles Associated with Treatment Response in Oligodendrogliomas
French, P. J., Swagemakers, S. M. A., Nagel, J. H. A., Kouwenhoven, M. C. M., Brouwer, E., van der Spek, P. J., Luider, T. M., Kros, J. M., van den Bent, M. J., & Smitt, P. A. E. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1886 · Cited by 116
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma
Kreisl, T. N., Zhang, W., Odia, Y., Shih, J. H., Butman, J. A., Hammoud, D. A., IWAMOTO, F. M., Sul, J., & Fine, H. A. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor091 · Cited by 113
Enhanced chemotherapy delivery by intraarterial infusion and blood‐brain barrier disruption in malignant brain tumors
Fortin, D., Desjardins, A., Benko, A. J., Niyonsega, T., & Boudrias, M. (2005) · Cancer · doi:10.1002/cncr.21112 · Cited by 113
Initial chemotherapy in gliomatosis cerebri
Sanson, M., Cartalat‐Carel, S., Taillibert, S., Napolitano, M., Djafari, L., Cougnard, J., Gervais, H., Laigle–Donadey, F., Carpentier, A., Mokhtari, K., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000129985.39973.e4 · Cited by 113
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy
Gilbert, M. R., Friedman, H. S., Kuttesch, J. F., Prados, M. D., Olson, J. J., Reaman, G. H., & Zaknoen, S. L. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.4.261 · Cited by 113
Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis
Larsen, V. A., Simonsen, H. J., Law, I. G., Larsson, H. B. W., & Hansen, A. E. (2012) · Neuroradiology · doi:10.1007/s00234-012-1127-4 · Cited by 112
Recurrent Glioblastoma: Where we stand
Roy, S., Lahiri, D., Maji, T., & Biswas, J. (2015) · South Asian Journal of Cancer · doi:10.4103/2278-330x.175953 · Cited by 112
Retracted
Primary CNS lymphoma
Hochberg, F. H., Baehring, J. M., & Hochberg, E. P. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0395 · Cited by 112
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab
Wefel, J. S., Cloughesy, T. F., Zazzali, J. L., Zheng, M., Prados, M., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor024 · Cited by 112
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)
Butowski, N. A., Chang, S. M., Junck, L., DeAngelis, L. M., Abrey, L. E., Fink, K., Cloughesy, T. F., Lamborn, K. R., Salazar, A. Μ., & Prados, M. D. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9693-3 · Cited by 112
Pseudoprogression Following Chemoradiotherapy for Glioblastoma Multiforme
Sanghera, P., Perry, J., Sahgal, A., Symons, S. P., Aviv, R. I., Morrison, M., Lam, K., Davey, P., & Tsao, M. N. (2010) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100009628 · Cited by 111
Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges
Zhang, J., Liu, H., Tong, H., Wang, S., Yang, Y., Liu, G., & Zhang, W. (2017) · Contrast Media & Molecular Imaging · doi:10.1155/2017/7064120 · Cited by 111
The Survival Effect of Repeat Surgery at Glioblastoma Recurrence and its Trend: A Systematic Review and Meta-Analysis
Lu, V. M., Jue, T. R., McDonald, K. L., & Rovin, R. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.04.016 · Cited by 111
Pseudoprogression after glioma therapy: a comprehensive review
Kruser, T. J., Mehta, M. P., & Robins, H. I. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.7 · Cited by 110
Response Assessment in Neuro-Oncology
Lee, E. Q., & Wen, P. Y. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0143-y · Cited by 110
Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances
Nieder, C., Adam, M., Molls, M., & Grosu, A. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.06.007 · Cited by 110
Intra-Arterial Delivery of Bevacizumab after Blood-Brain Barrier Disruption for the Treatment of Recurrent Glioblastoma: Progression-Free Survival and Overall Survival
Burkhardt, J., Riina, H. A., Shin, B. J., Christos, P. J., Kesavabhotla, K., Hofstetter, C. P., Tsiouris, A. J., & Boockvar, J. A. (2011) · World Neurosurgery · doi:10.1016/j.wneu.2011.05.056 · Cited by 110
Lymph node metastases
Santin, A. D. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000101)88:1 · Cited by 103
Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP‐16: A Children's Oncology Group phase II study
Korones, D. N., Fisher, P. G., Kretschmar, C. S., Zhou, T., Chen, Z., Kepner, J. L., & Freeman, C. R. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21154 · Cited by 110
Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly‐diagnosed with central nervous system atypical teratoid/rhabdoid tumors: The head start III experience
Zaky, W. T., Dhall, G., Ji, L., Haley, K., Allen, J. C., Atlas, M. P., Bertolone, S. J., Cornelius, A. S., Gardner, S. L., Patel, R., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24648 · Cited by 110
MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice
Essig, M., Anzalone, N., Combs, S. E., Dörfler, A., Lee, S.-K., Picozzi, P., Rovira, À., Weller, M., & Law, M. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2640 · Cited by 113
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
Kreisl, T. N., Kotliarova, S. E., Butman, J. A., Albert, P. S., Kim, L., Musib, L. C., Thornton, D., & Fine, H. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop042 · Cited by 109
Salvage chemotherapy With CPT-11 for recurrent meningioma
Chamberlain, M. C., Tsao-Wei, D. D., & Groshen, S. G. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9093-x · Cited by 109
Primary brain lymphomas after kidney transplantation: presentation and outcome
Snanoudj, R., Dürrbach, A., Leblond-Missenard, Caillard, S., de Ligny, B. H., Noël, C., Rondeau, É., Moulin, B., Mamzer, M., Lacroix, C., et al. (2003) · Transplantation · doi:10.1097/01.tp.0000079253.06061.52 · Cited by 109
Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
Kovacs, R. J., Maldonado, G., Azaro, A., Fernández, M. S., Romero, F. L., Sepulveda-Sánchez, J. M., Corretti, M., Carducci, M., Dolan, M., Gueorguieva, I., et al. (2015) · Cardiovascular Toxicology · doi:10.1007/s12012-014-9297-4 · Cited by 108
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
Rodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0192-4 · Cited by 108
Toxicity and Efficacy of Carboplatin and Etoposide in Conjunction with Disruption of the Blood-Brain Tumor Barrier in the Treatment of Intracranial Neoplasms
Williams, P. C., Henner, W. D., Simon, R.-G., Dahlborg, S. A., Brummett, R. E., Tableman, M., Dana, B. W., & Neuwelt, E. A. (1995) · Neurosurgery · doi:10.1097/00006123-199507000-00003 · Cited by 108
Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients
Plotkin, S. R., Halpin, C. F., McKenna, M. J., Loeffler, J. S., Batchelor, T. T., & Barker, F. G. (2010) · Otology & Neurotology · doi:10.1097/mao.0b013e3181eb328a · Cited by 108
Hydroxyurea Chemotherapy for Unresectable or Residual Meningioma
Newton, H. B., Slivka, M. A., & Stevens, C. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1026770624783 · Cited by 107
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Khan, R. B., Raizer, J. J., Malkin, M. G., Bazylewicz, K. A., & Abrey, L. E. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.1.39 · Cited by 107
Glioblastoma: Background, Standard Treatment Paradigms, and Supportive Care Considerations
Ellor, S. V., Pagano-Young, T. A., & Avgeropoulos, N. G. (2014) · The Journal of Law Medicine & Ethics · doi:10.1111/jlme.12133 · Cited by 106
18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab
Harris, R. J., Cloughesy, T. F., Pope, W. B., Nghiemphu, P. L., Lai, A., Zaw, T., Czernin, J., Phelps, M. E., Chen, W., & Ellingson, B. M. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos141 · Cited by 106
Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria
Pérez‐Larraya, J. G., Lahutte, M., Petrirena, G. J., Reyes-Botero, G., González-Aguilar, A., Houillier, C., Guillevin, R., Sanson, M., Hoang‐Xuan, K., & Delattre, J. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos070 · Cited by 106
Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial
Buchroithner, J., Erhart, F., Pichler, J., Widhalm, G., Preusser, M., Stockhammer, G., Nowosielski, M., Iglseder, S., Freyschlag, C. F., Oberndorfer, S., et al. (2018) · Cancers · doi:10.3390/cancers10100372 · Cited by 106
Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study
Pels, H., Juergens, A., Glasmacher, A. G., Schulz, H., Engert, A., Linnebank, M., Schackert, G., Reichmann, H., Kroschinsky, F., Vogt‐Schaden, M., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9712-4 · Cited by 106
Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
Omuro, A. M. P., Beal, K. P., Gutin, P. H., Karimi, S., Correa, D. D., Kaley, T. J., DeAngelis, L. M., Chan, T. A.-T., Gavrilovic, I. T., Nolan, C. P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0822 · Cited by 109
Non-Resectable Slow-Growing Meningiomas Treated by Hydroxyurea
Loven, D., Hardoff, R., Bar‐Sever, Z., Steinmetz, A., Gornish, M., Rappaport, Z. H., Fenig, E., Ram, Z., & Sulkes, A. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000021827.85754.8e · Cited by 105
Canadian Recommendations for the Treatment of Recurrent or Progressive Glioblastoma Multiforme
Easaw, J. C., Mason, W. P., Perry, J., Laperrière, N., Eisenstat, D. D., Maestro, R. F. D., Bélanger, K., Fulton, D. S., & Macdonald, D. R. (2011) · Current Oncology · doi:10.3747/co.v18i3.755 · Cited by 105
Self-citation
Biologic Activity of Tamoxifen at Low Doses in Healthy Women
DeCensi, A., Bonanni, B., Guerrieri‐Gonzaga, A., Gandini, S., Robertson, C., Johansson, H. A., Travaglini, R., Sandri, M. T., Tessadrelli, A., Farante, G., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1461 · Cited by 105
Quantitative imaging biomarkers in neuro-oncology
Waldman, A. D., Jackson, A., Price, S. J., Clark, C. A., Booth, T. C., Auer, D. P., Tofts, P. S., Collins, D. J., Leach, M. O., & Rees, J. H. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.92 · Cited by 104
Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?
Shah, A. H., Snelling, B., Bregy, A., Patel, P. R., Tememe, D., Bhatia, R. G., Sklar, E. M., & Komotar, R. J. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1059-9 · Cited by 104
Rechallenge with temozolomide in patients with recurrent gliomas
Wick, A., Pascher, C., Wick, W., Jauch, T., Weller, M., Bogdahn, U., & Hau, P. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5006-9 · Cited by 104
Salvage treatment with etoposide (VP‐16), ifosfamide and cytarabine (Ara‐C) for patients with recurrent primary central nervous system lymphoma
Arellano‐Rodrigo, E., López‐Guillermo, A., Bessell, E. M., Nomdedeu, B., Montserrat, E., & Graus, F. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.00045.x · Cited by 104
Machine learning and glioma imaging biomarkers
Booth, T. C., Williams, M., Luis, A., Cardoso, M. J., Ashkan, K., & Shuaib, H. (2019) · Clinical Radiology · doi:10.1016/j.crad.2019.07.001 · Cited by 103
Histopathology‐validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo‐progression in glioblastoma
Akbari, H., Rathore, S., Bakas, S., Nasrallah, M. P., Shukla, G., Mamourian, E., Rozycki, M., Bagley, S. J., Rudie, J. D., Flanders, A. E., et al. (2020) · Cancer · doi:10.1002/cncr.32790 · Cited by 105
Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on “Head Start” III: a multi-institutional, prospective clinical trial
Dhall, G., O’Neil, S., Ji, L., Haley, K., Whitaker, A. M., Nelson, M. D., Gilles, F. H., Gardner, S. L., Allen, J. C., Cornelius, A. S., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa102 · Cited by 103
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours
Poulsen, H. S., Grunnet, K., Mau‐Sørensen, M., Olsen, P., Hasselbalch, B., Nelausen, K. M., Kosteljanetz, M., & Lassen, U. (2008) · Acta Oncologica · doi:10.1080/02841860802537924 · Cited by 102
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults
Kesari, S., Schiff, D., Henson, J. W., Muzikansky, A., Gigas, D. C., Doherty, L. M., Batchelor, T. T., Longtine, J. A., Ligon, K. L., Weaver, S., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-005 · Cited by 102
Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma
Minniti, G. C., Sanctis, V. D., Muni, R., Rasio, D., Lanzetta, G., Bozzao, A., Osti, M. F., Salvati, M., Valeriani, M., Cantore, G. P., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9689-z · Cited by 102
Increased xCT Expression Correlates With Tumor Invasion and Outcome in Patients With Glioblastomas
Takeuchi, S., Wada, K., Toyooka, T., Shinomiya, N., Shimazaki, H., Nakanishi, K., Nagatani, K., Otani, N., Osada, H., Uozumi, Y., et al. (2012) · Neurosurgery · doi:10.1227/neu.0b013e318276b2de · Cited by 108
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
den Hollander, M. W., Bensch, F., Glaudemans, A. W. J. M., Munnink, T. H. O., Enting, R. H., den Dunnen, W. F. A., Heesters, M. A. A. M., Kruyt, F. A. E., Hooge, M. N. L., de Groot, J. C., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154401 · Cited by 104
BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors
Reithmeier, T., Graf, E., Piroth, T., Trippel, M., Pinsker, M. O., & Nikkhah, G. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-30 · Cited by 107
Diffusion-weighted MR Imaging for the Differentiation of True Progression from Pseudoprogression Following Concomitant Radiotherapy with Temozolomide in Patients with Newly Diagnosed High-grade Gliomas
Lee, W. J., Choi, S. H., Park, C., Yi, K. S., Kim, T. M., Lee, S., Kim, J., Sohn, C., Park, S., & Kim, I. H. (2012) · Academic Radiology · doi:10.1016/j.acra.2012.06.011 · Cited by 102
Temozolomide: a milestone in neuro-oncology and beyond?
Mutter, N., & Stupp, R. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.8.1187 · Cited by 102
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study
Bagatell, R., Norris, R. E., Ingle, A. M., Ahern, C. H., Voss, S. D., Fox, E., Little, A., Weigel, B. J., Adamson, P. C., & Blaney, S. M. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24874 · Cited by 103
Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide
Minniti, G. C., Salvati, M., Arcella, A., Buttarelli, F. R., D’Elia, A., Lanzetta, G., Esposito, V., Scarpino, S., Enrici, R. M., & Giangaspero, F. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0324-4 · Cited by 101
MR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas
Liu, X., Tian, W., Kolar, B. S., Yeaney, G. A., Qiu, X., Johnson, M. D., & EKHOLM, S. E. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq197 · Cited by 101
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Omuro, A. M. P., Chan, T. A.-T., Abrey, L. E., Khasraw, M., Reiner, A. S., Kaley, T. J., DeAngelis, L. M., Lassman, A. B., Nolan, C. P., Gavrilovic, I. T., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos295 · Cited by 101
Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question
Nasseri, M. N., Gahramanov, S., Netto, J. P., Fu, R., Muldoon, L. L., Várallyay, C. G., Hamilton, B. E., & Neuwelt, E. A. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not328 · Cited by 101
Promise and pitfalls of quantitative imaging in oncology clinical trials
Kurland, B. F., Gerstner, E. R., Mountz, J. M., Schwartz, L. H., Ryan, C. W., Graham, M. M., Buatti, J. M., Fennessy, F. M., Eikman, E. A., Kumar, V., et al. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2012.06.009 · Cited by 101
Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme
Baumann, F., Bjeljac, M., Kollias, S., Baumert, B. G., Brandner, S., Rousson, V., Yonekawa, Y., & Bernays, R. L. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000021803.01170.03 · Cited by 101
Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients
Rieger, J., Bähr, O., Müller, K., Franz, K., Steinbach, J. P., & Hattingen, E. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0098-8 · Cited by 100
ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma
Nowosielski, M., Recheis, W. A., Goebel, G., Güler, Ö., Tinkhauser, G., Kostron, H., Schocke, M. F. H., Gotwald, T. F., Stockhammer, G., & Hutterer, M. (2010) · Neuroradiology · doi:10.1007/s00234-010-0808-0 · Cited by 100
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme
Peereboom, D. M., Ahluwalia, M. S., Ye, X., Supko, J. G., Hilderbrand, S. L., Phuphanich, S., Nabors, B., Rosenfeld, M. R., Mikkelsen, T., & Grossman, S. A. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos322 · Cited by 103
Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab
Ellingson, B. M., Cloughesy, T. F., Lai, A., Nghiemphu, P. L., Mischel, P. S., & Pope, W. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq206 · Cited by 100

Authors: Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G.
Affiliations: Western University (CA)
ORCID: Cairncross, J G
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1990-07
Volume: 8
Issue: 7
Pages: 1277-1280
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1990.8.7.1277
OpenAlex: W1959628099
Cited by: 2,409
References: 11
Citations by year: 2026: 31 · 2025: 21 · 2024: 36 · 2023: 52 · 2022: 53 · 2021: 59 · 2020: 68 · 2019: 75 · 2018: 97 · 2017: 111 · 2016: 125 · 2015: 122 · 2014: 161 · 2013: 186 · 2012: 145
FWCI: 3.90
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: high-grade glioma, supratentorial glioma, response criteria, tumor size measurement, complete response, partial response, stable disease, progressive disease, steroid use, neurologic findings, patient selection, magnetic resonance imaging, computed tomography
MeSH terms: Diagnostic Errors, Drug Evaluation, Glioma, Humans, Magnetic Resonance Imaging, Medical Oncology, Tomography, X-Ray Computed, Supratentorial Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Response criteria for phase II studies of supratentorial malignant glioma.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks